Summary:
Patients with poor-risk acute leukaemia (AL), such as those with karyotypic abnormalities, t(9:22);t(4:11) and other gene rearrangements involving 11q23, frequently relapse on chemotherapy 1 and also have a high rate of relapse following bone marrow transplantation (BMT). 2, 3 Even after extensive searches of unrelated donor (UD) panels the only available donor may be mismatched at one or more HLA loci, a situation which has been associated with increased rates of primary, 4 and secondary graft failure and severe GVHD. 5 T cell depletion (TCD) of allografts, using monoclonal antibodies or other technologies in the mismatched related and UD setting have been successful in reducing the incidence and severity of acute (a)GVHD. 6, 7 However, relapse and rejection remain problematic. [8] [9] [10] The latter may be circumvented by infusing increased numbers of stem cells. 6, 11 Cellular immunotherapy using donor leukocyte infusions (DLI) has been shown to be an effective treatment for clinical and subclinical (cytogenetic and/or molecular) relapse in both chronic and acute leukaemias. 12, 13 The kinetics of disease relapse favour the treatment of patients with recurring chronic myeloid leukaemia (CML) following BMT. Less success has been achieved for patients with AL who relapse after BMT, although prior achievement of minimal residual disease (MRD) with chemotherapy may increase the response rate.
14 It may be possible to give pre-emptive DLI in the absence of aGVHD in patients with AL, who have evidence of MRD pre and/or post-BMT, or where there is unstable chimerism with increasing numbers of recipient cells. 15 This treatment is an interesting option for high-risk patients following BMT, especially if severe aGVHD can be limited by the timing of the T cell infusions. 16 The availability of donor T cells would facilitate such protocols, and cryopreservation does not impair functional responses, eg to mitogens. 17 This would be advantageous since reaccessing unrelated donors may be time consuming. A component allograft comprising a CD34 + cell-enriched fraction and an unadsorbed fraction (for DLI) may be advantageous.
Although one group has reported a low incidence of aGVHD in matched siblings receiving CD34 + cell-selected PBSC allografts, 18 most reports suggested that the reduction of T cells by CD34
+ immunoselection combined with posttransplant cyclosporin A (CsA) Ϯ methotrexate may not be sufficient prophylaxis against grade 2-4 aGVHD. 19, 20 An 118 increased severity of aGVHD might be expected in recipients of UD grafts and this was our experience when we transplanted CD34 + cell-selected marrow allografts from unrelated donors to four children with acute lymphoblastic leukaemia (ALL). 21 This contrasted with our previous experience where minimal aGVHD was seen in children receiving UD BM allografts purged of T cells by Campath-1M monoclonal antibody. 22 Discrepancies between the apparent TCD and development of aGVHD in these studies might be explained by the continued destruction or modulated activity of Campath-1M-coated T cells in vivo.
Further depletion of T cells from CD34 + cell-selected BM allografts is probably required to reduce the risk of aGVHD in UD transplants. We studied clinical scale allografts to evaluate the degree of TCD by flow cytometric and functional assays in bone marrow, following either a single or double T cell depletion strategy. For single depletion, CD34
+ cell selection was compared with in vitro treatment of BM allografts purged with Campath-1M; for double depletion, CD34 + cell selection was followed by Campath-1M or passage through a second immunoaffinity column to deplete CD2 + cells. Since total nucleated cell numbers and CD34 + cell content have been shown to enhance engraftment across histocompatibility barriers, 11, 23 the recovery of these parameters and the progenitor proliferative potential was assessed for each fraction.
Materials and methods

Preparation of bone marrow allografts
Bone marrow was collected from volunteer donors (n = 6) with informed consent, filtered using a blood administration set (Avon Medicals, Hythe, UK) and the mononuclear cells (MNC) harvested using a Cobe Spectra (Cobe, International Ltd, Zaventem, Belgium). The CD34 + cell content was measured by flow cytometry (see below) and a double TCD performed where the CD34 + cell yield was у8 × 10 6 /kg recipient body weight (in 5/6 cases, there was a size disparity between an adult donor and paediatric recipient) following MNC harvesting. The marrow was divided into two fractions one of which was purged of T cells using Campath-1M plus human complement (n = 4) and infused: one patient received a T replete BM allograft. CD34 + cells were selected from the remainder using the CEPRATE SC System (CellPro, Bothel, WA, USA) ( Figure 1 ). DLIs were prepared from the unadsorbed fraction following CD34 + cell selection. The adsorbed material was subjected to a second TCD protocol (described below), cryopreserved and reserved for further therapy as required. In the sixth case, BM was specifically harvested as a source of cells for DLI therapy from a sibling donor in whom venesection and apheresis were prohibited by lack of suitable venous access and where central line placement was not appropriate.
Campath treatment of cells
Campath-1M monoclonal antibody was prepared by precipitation with ammonium sulphate of the culture supernatant of cells grown in a hollow fibre fermentor. It works by complement-mediated lysis to deplete T cells from bone marrow allografts. Briefly, antibody was added to the marrow MNC to a final concentration of 0.1 mg/ml in all experiments. Following a 25 min incubation at room temperature, human AB serum, which had previously been tested for CH 50 complement activity, was added to give a final concentration of 25% v/v. 24 The sample was agitated at 15 min intervals during a 45 min incubation at 37°C. Sterile Hank's balanced salt solution (Gibco, Paisley, UK) was added to the marrow cells and this bag was spun at 1000 g for 4 min. Using a plasma extractor, the supernatant containing excess antibody and cell debris was removed carefully and the cells resuspended in human serum albumin (Zenalb, Elstree, UK). A 1.0 ml aliquot was removed to assess cell counts, viability percentages, phenotypic analysis and clonogenic potential.
Separation of CD34
+ cells (clinical scale)
We used clinical scale CEPRATE columns (CellPro) to separate CD34 + cells from the BM allograft as described previously. 25 Two ml aliquots were removed from the CD34 + cell enriched and unadsorbed fractions for cell counts, viabilities, phenotypic and clonogenic analysis. Following assessment of the CD3 + cell content in the unadsorbed fraction, graded aliquots ranging from 10 5 to 10 7 CD3 + cells/kg recipient body weight were frozen down as a potential source of T cell add-backs if required. A 10 ml aliquot was removed from the CD34 + cell-enriched product and treated with Campath-1M at a concentration of 0.1 mg/ml and complement (as described above) while the remainder of this material was depleted of CD2 + cells using a second immunoaffinity column (CellPro). A biotinylated antibody specific for the CD2 + antigen was added to the CD34 + cell-enriched fraction and following a 25 min incubation this fraction was processed through a second column, with the retention of CD2 + cells and the release of the CD34 + cells. Two ml aliquots of the double-depleted products were acquired and tested for MNC recovery, phenotype and clonogenic assays (see below). In all cases, the CD34 + cell-selected/CD2 + cell-depleted product was frozen down.
Cell counts and viability
Cell counts were assessed using the Sysmex SE 9000 (Tao Instruments, Kobe, Japan). Trypan blue exclusion was used to assess the viability of all fractions.
Analysis of immunophenotype
Phenotypic analyses of all samples (A-F in Figure 1 ) were performed by flow cytometry on the Coulter Excel (Coulter Electronics, Luton, UK) as we have described previously. 17 The following antigens were assessed; CD45 + (Sigma Diagnostics, St Louis, MO, USA), CD3
+ (Coulter Electronics). A minimum of 50 000 gated events was assessed for the start fraction, Campath-1M-treated and unadsorbed fractions. However, due to the low cell numbers in the CD34 + cell-enriched fractions, a mini- 
CD34
+ subset analysis CD34 + subset analysis was performed using tri-colour analysis using phycoerythrin-cyanin (Cy5)-conjugated CD34 + , FITC-conjugated HLA-DR and PE-conjugated CD38 antibodies (Coulter Electronics). Appropriate nonrelevant controls were used and the percentages of CD34 + cell subsets were analysed using the Coulter Excel System 11 software. A minimum of 200 000 events was assessed in Fractions A, B and D and, for CD34 + -selected material, a minimum of 30 000 events was analysed.
Progenitor assays
The content of granulocyte-macrophage CFU (CFU-GM) and erythroid burst-forming units (BFU-E) progenitors was evaluated in all fractions (A-F in Figure 1) . 26 Cultures were plated in triplicate for the CD34 + cell enriched, CD34 + cellenriched/CD2
+ -depleted and CD34
+ cell-enriched + Campath-1M-treated fractions at 10 3 cells/plate, for the MNC (start) fraction and Campath-1M-treated sample at 10 4 cells/plate and for the unadsorbed fraction at 10 5 cells/plate. Following 14 days incubation at 37°C in 5% CO 2 colonies were counted using an inverted microscope. The frequency of progenitors in a given sample was determined from the number of CFU-GM or BFU-E/cells plated (see above).
Limiting dilution assay (LDA) for T cells
To assess the frequency of T cells in the various fractions, a limiting dilution assay was performed. 27 Cells were dispensed in Terasaki plates (Greiner Labortechnik, Frickenhausen, Germany) at concentrations of 3-50 cells per well (start and unadsorbed fractions), 50-900 cells/well (CD34 + cell-enriched and CD34
+ cell-enriched + CD2 + -depleted) or 300-2700 cells per well (Campath-1M-treated and CD34 + cell-enriched plus Campath-1M-treated samples) in a total volume of 20 l. Replicates (60 wells each) were set up at the various cell concentrations (n = 5 for each sample). A line of best fit was established through the points and the frequency of T lymphocytes in a given sample was determined.
Results
Depletion of T and B cells
The T cell content from bone marrow allografts was assessed in fractions following single (CD34 + cell selection or Campath-1M treatment) or double (CD34 + cell selection plus CD2
+ cell depletion or CD34 + cell selection plus Campath-1M treatment) TCD and is shown in Table 1 . Flow cytometric analysis suggested that with one procedure, the mean depletion of T cells from either CD34
+ cell-selected material or that treated with Campath-1M was similar, 2.7 and 2.1 log, respectively. Using a functional LDA, the mean frequency of clonable T cells in the latter (1:2860) was approximately a log less than that seen with immunoselection (1:240), however, due to the different cell yields with each procedure, there was no difference in the depletion of clonable T cells in either fraction (Table 1) . When CD2 + cell depletion was used in conjunction with CD34 + cell selection, there was a further log depletion of T cells to 3.4 log ( Table 1 ). The frequency of clonable T cells, as estimated by LDA, also decreased from 1:240 to 1:980 (3.52 log, Table 1 ). Addition of Campath-1M monoclonal antibody to a CD34
+ cell-selected sample resulted in an additional 2 log depletion of T cells from CD34
+ cells resulting in a total TCD in excess of 4 log. These data were confirmed by the low frequency (1:4100) and recovery of clonable T cells in this sample as compared to the other fractions (Table 1) .
In the unadsorbed sample, there was minimal loss of CD3 + cells (14 Ϯ 11%, mean Ϯ s.d.) and the T cell frequency was similar to that of the starting material indicating the presence of functional T cells (Table 1) . These were frozen down in graded aliquots from 10 5 to 10 7 CD3
+ cells/kg body weight of recipient and stored. Estimation of the mean percent CD4 + , CD8 + and CD56 + cells (18, 11 and 1%) in the unadsorbed fraction was comparable with those of the start fraction (16, 10 and 1%, respectively, Table 2 ).
Purging of allografts using Campath-1M alone depleted both T and B cells by 2.04 and 1.57 logs, respectively. However, natural killer (NK) cells (CD56 + ) were relatively resistant to such treatment (56 Ϯ 38% recovery, Table 2 ). This differed from the CD34 + cell-selected material where T , B and NK cell populations were equally deselected ( Table 2) . With either double depletion strategy, the NK cell population represented less than 0.5% of the cells due to their deselection in the initial CD34 + cell selection step. The combination of Campath-1M treatment following CD34 + cell selection, resulted in further depletion of both T and B cells. In comparison, while sequential CD2 + cell depletion following CD34 + cell selection enhanced the depletion of T cells (3.4 log), the mean B cell population remained unchanged and accounted for 20 Ϯ 18% of the remaining product, an overall I.6 log depletion ( Table 2) .
Recovery of CD34
+ cells and progenitors
CD34
+ cell recovery and progenitor proliferative potential for both myeloid and erythroid series were assessed. With all forms of processing, there were losses of both CD34 + cells and committed progenitors. Where either Campath-1M or CD34
+ cell selection was carried out alone, there was a 64 and 37% recovery of CD34 + cells; 63 and 31% recovery of committed myeloid progenitors and 66 and 25% recovery of erythroid progenitors, respectively (Figure 2) . Although a mean of 34 Ϯ 19% CD34
+ cells was recovered in the unadsorbed fraction (D), the proliferative potential (frequency) of myeloid and erythroid progenitors in this fraction was much lower than that of the Cobe processed (start) sample (Table 3 ). This accounted for the 6 Ϯ 3% myeloid and 10 Ϯ 5% erythroid recoveries (Figure 2) . Double TCD caused further loss of both CD34 + cells and progenitors (Table 3 ). The overall recovery of CD34 + cells following immunoselection and Campath-1M treatment was 20 Ϯ 4% compared with 28 Ϯ 2% for the two-step immunoaffinity protocol (Figure 1, Fraction E) . Following CD34 + cell enrichment and regardless of the subsequent TCD method, the frequency of myeloid and erythroid progenitors was similar in all samples ( Table 3 ). The recovery of myeloid and erythroid progenitors following the sequential immunoaffinity method for TCD was 25 Ϯ 8% and 17 Ϯ 3%, respectively, whereas for CD34 + selection followed by Campath-1M, the recoveries were 18 Ϯ 8% and 16 Ϯ 8% (Figure 2 ). The presence of CD34 + CD38 − HLA-DR − cells in fractions following either single or double depletion suggested that more primitive cells were not preferentially lost during processing (Table 4) .
Discussion
A potential advantage of CD34
+ cell selection over antibody purging is that the technique generates a component allograft comprising a stem and progenitor cell enriched fraction for transplantation and an unadsorbed fraction con- taining 85% functional T cells which may be stored in graded aliquots to support post-transplant immunotherapy where necessary. 25 This strategy may provide the preferred therapeutic option in patients considered to be at high risk of relapse. Our initial experience with bone marrow suggested that selection of CD34 + cells using the CEPRATE column resulted in a 2.2 log reduction of T cells. However, in paediatric ALL patients receiving UD-BMT, this was not sufficient to prevent severe aGVHD. 20 A subsequent report by Espérou et al 28 in an adult/paediatric patient mix, suggested that a higher CD34
+ cell purity and hence a greater T cell depletion (3.25 log) could be achieved with bone marrow using the Isolex 300 Baxter device. Despite the decrease in T cell content, there was significant aGVHD (grades 2-3) in 7/25 patients who engrafted.
Following administration of G-CSF, mobilisation of T cells (as well as CD34
+ cells) has been documented.
CD34
+ cell selection was evaluated as a mechanism of T cell purging to reduce the incidence of acute and chronic GVHD after PBSC allografts. In one report where CsA and prednisolone were administered as post-transplant immunosuppression, rapid engraftment was achieved without significant aGVHD in 20 patients receiving CD34
+ cell-selected matched sibling PBSC allografts. 18 However, the more common clinical experience with such grafts suggests that the reduction of T cells by CD34 + immunoselection combined with post-transplant cyclosporin A (CsA) Ϯ methotrexate may not be sufficient prophylaxis against grades 2-4 aGVHD. The addition of methotrexate reduced the numbers of patients developing уgrade 3 aGVHD to 1/5 as compared to 4/5 receiving CsA alone 19 and 3/9 as compared to 3/5, respectively. 20 In the UD setting, further depletion of T cells will be necessary to minimise the increased incidence and severity of aGVHD due to undetected HLA disparities. 30 In this report we summarise our studies of two double TCD strategies of clinical scale allografts with evaluation of percent T and B cell depletion, CD34
+ cell recovery and progenitor proliferative potential. The double depletion strategies employed in this study resulted in a 3.4 and 4.05 log reduction of T cells where CD2 + cell depletion or Campath-1M treatment, respectively, were performed following CD34 + cell selection (Table 1) . These purging techniques equated to a mean dose reduction to 2 Ϯ 1 × 10 4 CD3 + cells/kg (CD34 + cell selection followed by CD2 + cell depletion) and a calculated T cell dose of 6 Ϯ 7 × 10 3 /kg (assuming all cells were processed) using CD34
+ cell selection plus Campath-1M treatment. The effective T cell dose may be even lower in the latter if Campath-coated lymphocytes continue to be destroyed in vivo or if their ability to proliferate has been affected. Clinical studies in the HLA-matched setting have suggested the development of aGVHD is unlikely to occur below 10 5 clonable T cells/kg. 31 Whether this depletion of T cells is adequate in the UD setting is as yet unknown.
EBV lymphoproliferative disease (LPD) post-BMT is a serious threat in immunocompromised patients. 32 Recent analysis indicated that patients receiving Campath-1M-treated grafts in which B cells are lysed are less likely to be at risk than those receiving either unmanipulated grafts or grafts where the T cells have been selectively depleted. 33 
With CD34
+ cell selection alone, the mean B cell content was reduced to 0.6 × 10 6 cells/kg from 25 × 10 6 /kg, a 1.6 log reduction from the starting material. Where an additional TCD strategy was employed (CD34 + cell selection followed by Campath-1M treatment), the B cell content was reduced by 2.52 log.
The loss of CD34 + cells and progenitors using bone marrow alone was unacceptably high (Table 3 and Figure 2) , and may restrict sequential TCD steps unless single BM harvests are supplemented and/or replaced with mobilised PBPC. Although in sibling BMT thresholds for CD34 + cells have been defined above in which there is increased patient survival and decreased transplant-related mortality, 34 these values have not yet been established in UD BMT. Furthermore, with rigorous TCD to Ͻ10 5 /kg body weight recipient, we can only speculate that higher stem cell doses may be needed to prevent rejection. Previous reports with haploidentical transplants suggest that high starting doses of CD34 + cells obtained by combining PBSC with BM and rigorous depletion of T cells resulted in prompt engraftment 6, 35 and a low incidence (6%) of significant aGVHD (уgrade 2). 6 Application of this technology for patients with 'high risk' ALL may facilitate rapid engraftment with minimal or no aGVHD allowing early pre-emptive DLI on detection of MRD or mixed chimaerism 36 and prevention of relapse which is the principal cause of death in ALL patients receiving T cell-depleted UD allogeneic BMT. 22 We confirmed that the percentage of CD34 + CD38 − HLA-DR − cells was not significantly reduced by purging implying no preferential loss of immature progenitors (Table 4) . Functional assays for primitive cells were not performed in this study but previous reports have confirmed the presence of long-term culture-initiating cells and cobblestone area-forming cells in the CD34 + CD33 − and CD38 − cells following a double procedure using CD34 + cell selection (CellPro) followed by depletion of T and B or neoplastic cells using the StemSep device. 37 Moreover, we observed no preferential loss of any CD34
+ cell subset although coexpression of CD52 has been observed on subsets of CD34 + cells. This accords with the findings of Gilleece and Dexter 38 who showed no decrease in the clonogenic potential of CD34
+ -purified cells with saturating concentrations of Campath-1H. Double TCD, using the techniques we have described and with large numbers of CD34 + cells may be a useful strategy to maximise engraftment, avoid clinical GVHD and will allow prophylactic/pre-emptive DLI, collected from the unadsorbed fraction during the selection procedure.
